CLINICAL TRIAL / NCT05669482

Inclusion Criteria: - Male or female subjects ≥ 18 years of age - Histologic or cytologic evidence of metastatic pancreatic ductal adenocarcinoma. - An Eastern Cooperative Group (ECOG) performance status ≤ 1 - Measurable disease according to RECIST 1.1 - Adequate organ function - Adequate cardiac function - Agreement to use highly effective method of contraceptive Exclusion Criteria: - Patients with pancreatic neuroendocrine tumors - Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma - Prior treatment with inhibitors of the RAS /MAPK pathway [e.g. MEK inhibitors] or inhibitors of FAK - History of prior malignancy, with the exception of curatively treated malignancies - Major surgery within 4 weeks (excluding placement of vascular access) - Concurrent heart disease or severe obstructive pulmonary disease - Concurrent ocular disorders - Active skin disorder that has required systemic therapy within the past 1 year - Patients with interstitial lung disease or pulmonary fibrosis or severe lung disease, pulmonary edema, and adult respiratory distress syndrome - Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy